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Abstract
Background: Variants of uncoupling protein genes UCP1 and UCP2 have been associated with a range of traits. We wished to
evaluate contributions of known UCP1 and UCP2 variants to metabolic traits in the Insulin Resistance and Atherosclerosis (IRAS)
Family Study.
Methods: We genotyped five promoter or coding single nucleotide polymorphisms (SNPs) in 239 African American (AA)
participants and 583 Hispanic participants from San Antonio (SA) and San Luis Valley. Generalized estimating equations using a
sandwich estimator of the variance and exchangeable correlation to account for familial correlation were computed for the test
of genotypic association, and dominant, additive and recessive models. Tests were adjusted for age, gender and BMI (glucose
homeostasis and lipid traits), or age and gender (obesity traits), and empirical P-values estimated using a gene dropping approach.
Results: UCP1 A-3826G was associated with AIRg in AA (P = 0.006) and approached significance in Hispanic families (P = 0.054);
and with HDL-C levels in SA families (P = 0.0004). Although UCP1 expression is reported to be restricted to adipose tissue, RT-
PCR indicated that UCP1 is expressed in human pancreas and MIN-6 cells, and immunohistochemistry demonstrated co-
localization of UCP1 protein with insulin in human islets. UCP2 A55V was associated with waist circumference (P = 0.045) in
AA, and BMI in SA (P = 0.018); and UCP2 G-866A with waist-to-hip ratio in AA (P = 0.016).
Conclusion: This study suggests a functional variant of UCP1 contributes to the variance of AIRg in an AA population; the
plausibility of this unexpected association is supported by the novel finding that UCP1 is expressed in islets.
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Background
Uncoupling proteins are mitochondrial inner membrane
electron carriers [1]. Uncoupling protein 2 (UCP2) inhib-
its glucose stimulated insulin secretion, and models of
type 2 diabetes are associated with increased expression in
islets [2]. Polymorphisms in the uncoupling protein genes
UCP1 (4q31.21) and UCP2 (11q13.4) have been associ-
ated with a number of measures of glucose homeostasis
and adiposity. These include associations between UCP2
G866A and A55V and glucose-induced insulin secretion
[3-5], as well as obesity and metabolism [6-8]. Associa-
tions with obesity, weight gain and metabolism [9-12]
have been reported for UCP1 variant A3826G, often act-
ing synergistically with β3-adrenergic receptor W64R, and
UCP1 A64T has also been associated with obesity [10]. In
addition, UCP1 A-3826G and M229L have been found to
be associated with type 2 diabetes [11,13].
Given the importance of UCP1 and UCP2 genes in metab-
olism, we chose to evaluate the five promoter or coding
variants in these two genes previously associated with
metabolic phenotypes (above) for associations in families
from the Insulin Resistance and Atherosclerosis (IRAS)
Family Study. The IRAS Family Study has recruited
extended African American and Hispanic families [14],
and extensive phenotypic data on measures of glucose
homeostasis, adiposity, and lipids have been collected on
participants. On detection of a significant association
between UCP1 SNPs and acute insulin response to glu-
cose (AIRg), we investigated the expression patterns of this
gene in mammalian pancreas.
Methods
Subjects
The IRAS Family Study design, recruitment and phenotyp-
ing have been described in detail [14]. Studies were con-
ducted using protocols approved by the human subjects
committees at each participating institution and all partic-
ipants provided informed consent. Briefly, multi-genera-
tional African American and Hispanic families were
initially recruited from probands of the original IRAS
cohort [15]. Ascertainment of the proband was based on
the sample size of available family members (with a target
of four living full siblings and five living offspring of these
siblings) and a range of glucose tolerance. Ascertainment
was supplemented with additional large non-IRAS fami-
lies recruited from the general population. Families were
not selected based on any phenotypic criteria. Participants
were from clinical centers in Los Angeles, California (Afri-
can American), San Luis Valley, Colorado (rural His-
panic), and San Antonio, Texas (urban Hispanic). The
clinical examination included height, weight, waist and
hip circumferences, fasting blood draw, computerized
tomography (CT) scanning for assessment of abdominal
fat area, and medical history interview. A total of 287 Afri-
can American individuals (18 families; family size ranged
from 4 to 51 family members) from Los Angeles, 318 His-
panic individuals (12 families; family size 4 to 39 mem-
bers) from San Luis Valley and 493 Hispanic individuals
(33 families; family size from 6 to 30 members) from San
Antonio were included in the analyses (Table 1).
Glucose homeostasis traits
The following traits related to glucose homeostasis were
tested for association with the UCP1 and UCP2 SNPs gen-
otyped: fasting plasma glucose; fasting plasma insulin;
acute insulin response to glucose (AIRg); and insulin
resistance, expressed as the insulin sensitivity index (SI).
Glucose values were obtained after a minimum 8 hour
fast. Plasma glucose and insulin levels were measured at
the University of Southern California, using the glucose
oxidase technique on an autoanalyzer and the insulin
Table 1: IRAS Family Study participant characteristics
African American Hispanic
Los Angeles San Luis Valley San Antonio
Families (n) 18 12 33
Family members per family (n) 4–51 4–39 6–30
Participantsa (n) 287 318 493
Female gender, % 56.5 52.2 60.0
Diabetes, % 11.6 12.8 17.7
Age, mean ± SD 43.8 ± 14.8 40.3 ± 14.0 43.6 ± 14.8
AIRg μU/mL ± SD 878.4 ± 768.2 808.1 ± 631.5 726.2 ± 620.1
SI, MINMOD, ± SD 1.75 ± 1.22 2.41 ± 2.00 1.95 ± 1.85
BMI, kg/m2 ± SD 28.8 ± 6.5 27.5 ± 5.6 30.1 ± 6.3
Waist, cm ± SD 89.3 ± 14.1 87.3 ± 13.2 92.9 ± 14.7
WHR, ratio ± SD 0.82 ± 0.08 0.85 ± 0.09 0.85 ± 0.08
HDL, mg/dL ± SD 48.3 ± 13.2 43.7 ± 12.4 42.4 ± 12.9
aIncludes only individuals from the IRAS Family Study cohort with at least one UCP1 or UCP2 SNP genotype. Individuals in these families with type 2 
diabetes have been excluded from AIRg and SI calculations. AIRg: Acute insulin response to glucose; SI: insulin sensitivity index; WHR: waist-to-hip 
ratio.BMC Endocrine Disorders 2007, 7:1 http://www.biomedcentral.com/1472-6823/7/1
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dextran-charcoal immunoassay [16]. Insulin sensitivity
was assessed by the frequently sampled intravenous glu-
cose tolerance test (FSIGT), using a reduced sampling pro-
tocol [17]. Glucose in the form of a 50% solution (0.3 g/
kg) and regular human insulin (0.03 μ/kg) were injected
through an intravenous line at 0 and 20 min, respectively.
Blood was collected at -5, 2, 4, 8, 19, 22, 30, 40, 50, 70,
100, and 180 min. Insulin resistance, expressed as the
insulin sensitivity index (SI), was calculated by mathemat-
ical modeling methods (MINMOD) [18]. Acute insulin
response to glucose (AIRg) was defined as the mean insu-
lin increment in the plasma insulin concentration above
the basal in the first 8 min after the administration of glu-
cose. Glucose values were obtained after a minimum 8
hour fast, and diabetes was diagnosed using the American
Diabetes Association criteria of fasting plasma glucose
value ≥ 126 mg/dL and/or current use of anti-diabetic
medications. Individuals with diabetes were excluded for
analyses of glucose homeostasis traits. One hundred
eighty-five participants had impaired fasting glycemia
(fasting glucose > 100 mg/dL).
Lipid traits
Lipid traits tested for association with UCP1 and UCP2
SNPs included: triglyceride; HDL-C; LDL-C; and total cho-
lesterol levels. Plasma was separated from blood collected
after a 12 h fast, and stored at -70°C prior to analysis.
Total cholesterol and triglyceride were measured using
enzymatic methods. LDL-C was calculated using the
Friedewald equation [19] if triglyceride was < 400 mg/dL
or otherwise by ultracentrifugation. HDL-C was measured
using the direct method [20].
Obesity and adiposity traits
Obesity traits used for association analyses included: waist
circumference; waist-to-hip ratio (WHR); BMI; visceral
adipose tissue (VAT); and subcutaneous adipose tissue
(SAT). Height, and waist and hip circumferences were
measured to the nearest 0.5 cm, and weight to the nearest
0.1 kg. BMI was calculated as weight (kg)/height (m)2.
Abdominal fat mass was measured at the L2/L3 and L4/L5
vertebral region by CT. Scans were read at the University
of Colorado Health Sciences Center, Department of Radi-
ology, for VAT and SAT. Bowel fat was subtracted out from
the VAT, and L4/L5 measures used in these analyses. A
small number of participants were missing L4/L5 data but
had L2/L3 data; for these participants L4/L5 data was
imputed from the L2/L3 data using a simple linear model.
UCP1 and UCP2 genotyping
Total genomic DNA was purified from whole blood using
the PUREGENE DNA Purification kit (Gentra Systems,
Minneapolis MN). Genotyping was conducted using a
MassARRAY system (Sequenom, San Diego CA) [21].
Primer sequences for UCP1 A-3826G, A64T, M229L, and
UCP2  G-866A and A55V, designed using SpectroDE-
SIGNER software (Sequenom, San Diego CA), are availa-
ble on request.
Statistical analyses
Relationship testing and genotyping error checking
As part of the broader IRAS Family Study efforts, pedigrees
were genotyped by the Mammalian Genotyping Service
(MGS), Marshfield WI, using 383 microsatellite markers.
Each pedigree was examined for consistency of the stated
family structure with the genome scan data using PREST,
version 2.01 [22,23]. In the 63 pedigrees used in this
investigation, a total of 28 likely misspecified familial
relationships were modified from 18 families. Genotypes
that showed inconsistency with Mendelian inheritance
were identified using PedCheck, version 1.1 [24], and
inconsistent genotypes converted to missing. All SNPs
were checked for consistency with Hardy Weinberg Equi-
librium (HWE).
Linkage disequilibrium
We estimated the degree of linkage disequilibrium (LD)
between SNPs using the standardized measure of D' [25],
where the joint probability of haplotype was estimated by
the expectation-maximization (EM) algorithm and the
respective allele frequencies were estimated based on
maximum likelihood estimates [26].
Association analyses
To explore associations among SNP polymorphisms and
quantitative measures, the marginal models incorporating
generalized estimating equations (GEE1) [27] were used.
This approach has been widely used in longitudinal data
analysis [28] and can account for the dependency between
correlated measures within a family. The method allows
separate modeling of the regression of quantitative meas-
ures on SNP polymorphisms and other covariates, and the
association among quantitative measures within each
family. An advantage of this method is that one need not
to specify the distribution of the outcome variable, just
the relationships between the marginal mean and vari-
ance, and between the marginal mean and covariates.
Another advantage is that even though the correlation
model among the related outcome measures may be spec-
ified incorrectly, the association model between the out-
come and covariates can still obtain a robust result. Here
familial correlation was accounted for using a sandwich
estimator of the variance and exchangeable correlation. A
family of power transformations conditional on the cov-
ariates age, gender, and BMI [29] was explored. To mini-
mize the heterogeneity of variance, the phenotypes were
transformed to best approximate the normality assump-
tions. We computed four tests of association for each SNP:
the overall test of genotypic association with two degrees
of freedom, as well as the statistical contrasts defined byBMC Endocrine Disorders 2007, 7:1 http://www.biomedcentral.com/1472-6823/7/1
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three genetic models – dominant, additive, and recessive.
Age, gender and BMI were included as covariates, except
for measures of adiposity where analyses were conducted
with and without BMI as a covariate. Marginal regression
coefficients have the same interpretation as those from an
analysis using unrelated individuals. Potential influential
points and outliers have been checked. The analyses were
stratified by center and performed using SAS software
(SAS Institute, Cary, NC).
To avoid the potential increase of type I error rate, we esti-
mated empirical pvalues for significant single SNP GEE
association analyses (P < 0.05 using the general model,
with mode of inheritance subsequently explored). We
used the gene dropping approach implemented in Men-
del, version 5.7 [30], to simulate 10,000 datasets based on
the IRAS Family Study pedigree structure under the null
hypothesis of no association between phenotype and gen-
otype data. The empirical p-value was determined as the
proportion of simulated data sets with statistics more
extreme than the observed value. Only empirical p-values
are presented since this approach is more conservative
and adjusts for deficiencies in the large sample approxi-
mation of the GEE method.
Two-marker (UCP1 and UCP2) and three-marker (UCP1
only) haplotypic associations were evaluated in each pop-
ulation separately using quantitative pedigree disequilib-
rium tests (QPDT) [31].
RT-PCR
Reverse Transcription-PCR (RT-PCR) was performed
using the SuperScript First Strand Synthesis System for RT-
PCR (Invitrogen Life Technologies, Carlsbad, CA), as
described by the manufacturer, using 1 μg total human
pancreas RNA (Ambion, Austin, TX). Two μl cDNA were
subsequently amplified in a total reaction volume of 50 μl
containing 0.2 mM dNTP, 1.5 mM MgCl2, and 200 nM of
each forward and reverse primer. Primers were specifically
designed in regions of low homology with the other UCP
genes and flanking one or more introns. For human UCP1
the following primers were used: forward primer 5'-
TGGAATAGCGGCGTGCTTG-3' (located in exon 1), and
reverse primer 5'-CTCATCAGATTGGGAGTAG-3' (exon
4), expected to produce a product of 489 bp. For human
UCP2, these primers were used: forward 5'-TCTACAAT-
GGGCTGGTTGC-3' (exon 2) and reverse 5'-
TGTATCTCGTCTTGACCAC-3' (exon 5), with an expected
product size of 495 bp. Control primers were for β-actin,
supplied in the SuperScript First Strand Synthesis System
for RT-PCR (Invitrogen Life Technologies, Carlsbad, CA).
Each reaction was denatured at 95°C for 2 minutes,
amplified using 40 cycles of 95°C for 30 seconds, 60°C
for 45 seconds, and 72°C for 30 seconds, and underwent
a final extension at 72°C for 3 minutes. Samples were
electrophoresed on a 1% agarose gel, products visualized
under UV light, and compared against a Ready-Load 1 Kb
Plus DNA Ladder (Invitrogen, Carlsbad, CA). Bands were
extracted using a QIAquick Gel Extraction Kit microcentri-
fuge protocol (Qiagen Sciences, Valencia, CA) and
sequenced on an ABI PRISM 3100 Genetic Analyzer
(Applied Biosystems, Foster City, CA) using Big Dye Ter-
minator v3.1 Cycle Sequencing Kits (Applied Biosystems,
Foster City, CA).
Total RNA was extracted from MIN-6 or αTC 1.6 cells and
reverse-transcribed to cDNA. 10 ng of cDNA was used in a
25  μl PCR reaction with AmpliTaq Gold Polymerase,
using the following amplification conditions for Ucp2:
95°C for 10 min, Hot-start, then 35 cycles of denaturation
at 95°C for 30 sec, annealing at 60°C for 30 sec and
amplification at 72°C for 30 sec. The same amount of
cDNA was used in 25 μl PCR reaction with AmpliTaq
Gold Polymerase to detect Ucp1. PCR conditions for Ucp1
were: 95°C for 10 min, Hot-start, followed by 3 cycles of
denaturation at 95°C for 30 sec, annealing at 54°C for 10
sec, extension at 72°C for 30 sec; another 3 cycles at 95°C
for 30 sec, 56°C for 15 sec and 72°C for 30 sec, and finally
35 cycles at 95°C for 30 sec, 58°C for 30 sec and 72°C for
30 sec. After the last cycle, samples were incubated for 5
min at 72°C. 15 μl of amplified products were then
resolved on a 1% agarose gel, and DNA bands visualized
under UV. Primers used to amplify mouse Ucp1 and Ucp2
products were UCP1-M F1, 5'-TATCATCACCTTC-
CCGCTG-3' (exon 1) ; UCP1-M R1, 5'-GTCATATGTTAC-
CAGCTCTG-3' (exon 4), product size 505 bp; UCP2-M
F2, 5'-TCTACAATGGGCTGGTCGC-3' (exon 4); UCP2-M
R5, 5'-CAAGCGGAGAAAGGAAGGC-3' (exon 8), product
size 608 bp. The quality of MIN-6 and αTC1.6 cDNA was
confirmed by PCR amplification of cyclophilin (data not
shown).
Immunohistochemistry
Formalin-fixed, paraffin embedded Macaca fascicularis
(monkey) pancreas was sectioned at 4 μm, and commer-
cially obtained normal human (BioChain, Haywood, CA)
and normal mouse pancreatic tissue sections (BioChain,
Haywood, CA) were used. Triplicate slides for each species
were used for the localization of (1) insulin, (2) UCP1,
and (3) insulin and UCP1. After sections were deparaffin-
ized, two sets of slides were incubated with Guinea pig
anti-porcine insulin (DAKO, Carpinteria, CA) at 1:100 for
60 minutes at 34°C, then incubated with biotinylated
anti-rabbit at 1:20 (BioGenex, San Ramon, CA) for 10
minutes at 34°C, and finally incubated for 20 minutes at
37°C with Streptavidin-β-Galactosidase at 1:250 (Gibco-
BRL, Gaithersburg, MD) and visualized using Gal-X. After
performing antigen retrieval, insulin-stained as well as
unstained sections were incubated with goat anti-UCP1
(Santa Cruz Biotechnology, Santa Cruz, CA) at 1:100 forBMC Endocrine Disorders 2007, 7:1 http://www.biomedcentral.com/1472-6823/7/1
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one hour at room temperature, incubated 10 minutes at
34°C in biotinylated rabbit anti-goat (Jackson Immu-
noResearch, West Grove, PA) at 1:250, then incubated
with Streptavidin-Alkaline phosphatase (BioGenex, San
Ramon, CA) at 1:20 for 10 minutes at 34°C. Vector Red
substrate (Vector Laboratories, Burlingame, CA) was used
for visualization, and sections were counterstained with
Mayer's hematoxylin. A MicroProbe system (Fisher Scien-
tific, Kent, WA) using capillary action, and commercially
purchased TRIS diluent and wash buffer (Biomeda, Foster
City, CA) with 0.1% Tween 20 to serve as a surfactant and
0.5% casein to block non-specific binding of proteins
were used.
Results
Study sample
Characteristics of the three IRAS Family Study popula-
tions are shown in Table 1. The mean ages of the partici-
pating family members were 43.8 ± 14.8 years (Los
Angeles), 40.3 ± 14.0 years (San Luis Valley) and 43.6 ±
14.8 years (San Antonio), with 52.2–60.0% female partic-
ipants. Using the Los Angeles population as the reference
group, the mean age of the San Luis Valley participants is
significantly lower than the Los Angeles participants (p =
0.0057). The prevalence of diabetes in the San Antonio
participants is higher than in the Los Angeles sample (p =
0.046) and the mean AIRg in the San Antonio sample is
significantly lower than that of the Los Angeles popula-
tion (p = 0.024). A higher AIRg in African American partic-
ipants, when compared with Hispanic participants, has
been reported previously for this study population
[23,32,33]. The mean waist measurement in San Antonio
family members (p = 0.043) is significantly greater than
that of the Los Angeles participants; and the mean WHR
in San Antonio (p = 0.0004) and San Luis Valley (p =
0.0028) samples are significantly higher than that of the
Los Angeles sample. The mean HDL in San Antonio (p <
0.0001) and San Luis Valley (p = 0.0057) families are
both significantly lower than in the Los Angeles families.
HWE, linkage disequilibrium between SNPs, and allele 
frequencies
All SNPs were consistent with HWE, except for UCP1 A-
3826G in the San Antonio Hispanic population (P =
0.034 for unrelated founder individuals, n = 73). There
was a single inconsistency (for UCP1 A64T in an individ-
ual from the San Luis Valley) among genotypes from 50
individuals included as blind duplicates, producing a gen-
otyping error rate of 0.4% and a concordance rate of >
99%. UCP1 SNPs were in high LD, with D' > 0.90 for all
pairwise comparisons across all three populations using
unrelated founders, except for A64T and M229L in the SA
founders where D' = 0.80. LD between the two UCP2
SNPs was high, with D' > 0.97 across all three popula-
tions. Genotype frequencies are shown in Table 2. UCP1
SNPs A64T and M229L were relatively rare, and recessive
effects of these SNPs were disregarded in this study.
Association between UCP1 and AIRg
A significant association was observed between UCP1 A-
3826G and AIRg in African American families (GEE empir-
ical P = 0.006, dominant model; Table 3). There was bor-
Table 2: Genotype frequencies for UCP1 and UCP2 SNPs in populations from the IRAS Family Study
African American Hispanic
Los Angeles San Luis Valley San Antonio
UCP1 A-3826G A/A, % (n)* 17.4 (50) 34.0 (108) 35.2 (174)
A/G, % (n) 40.4 (116) 51.9 (165) 50.4 (249)
G/G, % (n) 42.2 (121) 14.2 (45) 14.4 (71)
Total (n) (287) (318) (494)
A64T G/G, % (n) 83.1 (236) 83.8 (263) 83.1 (409)
G/A, % (n) 16.2 (46) 15.6 (49) 15.9 (78)
A/A, % (n) 0.7 (2) 0.6 (2) 1.0 (5)
Total (n) (284) (314) (492)
M229L A/A, % (n) 93.0 (264) 84.4 (265) 82.9 (402)
A/T, % (n) 7.0 (20) 14.7 (46) 16.1 (78)
T/T, % (n) 0 (0) 1.0 (3) 1.0 (5)
Total (n) (284) (314) (485)
UCP2 G-866A G/G, % (n) 32.8 (89) 31.1 (94) 27.2 (132)
G/A, % (n) 48.0 (130) 48.7 (147) 46.7 (227)
A/A, % (n) 19.2 (52) 20.2 (61) 26.1 (127)
Total (n) (271) (302) (486)
A55V C/C, % (n) 28.8 (82) 28.3 (89) 26.3 (129)
C/T, % (n) 51.2 (146) 53.3 (168) 47.4 (232)
T/T, % (n) 20.0 (57) 18.4 (58) 26.3 (129)
Total (n) (285) (315) (490)
*n = the number of individuals successfully genotyped.BMC Endocrine Disorders 2007, 7:1 http://www.biomedcentral.com/1472-6823/7/1
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derline evidence for an association between A-3826G and
AIRg in Hispanic families from San Luis Valley, Colorado
(GEE empirical P = 0.054, dominant model). Although
the initial GEE analysis provided evidence of an associa-
tion between A64T and AIRg in African Americans (unad-
justed p < 0.001, general model; P = 0.038, additive
model), this result was driven by the presence of two
minor allele homozygotes with high AIRg values and was
not supported by simulation-based empirical p-values (P
= 0.116, general model; P = 0.110, additive model). Hap-
lotypic association analyses of these two SNPs using
QPDT [31] were not significant (data not shown).
Other significant associations
Four other significant associations were detected (Table
3), with the majority related to measures of adiposity.
UCP2 A55V was associated with waist circumference (P =
0.045) and UCP2 G-866A with WHR in AA (P = 0.016),
although only in analyses unadjusted for BMI (but
adjusted for age and sex). UCP2 A55V was also associated
with BMI in SA (P = 0.018), and UCP1 A-3826G was asso-
ciated with HDL-C levels in SA families (P = 0.0004) after
adjustment for age and sex. Even though associations with
UCP2 A55V were across different populations, the direc-
tion of effects was consistent, with the 55V/55V genotype
associated with both greater waist circumference and
higher BMI.
RT-PCR of UCP1 and UCP2
Results of the RT-PCR analyses using total human pancre-
atic RNA are shown in Figure 1. There was no product vis-
ible when the protocol was carried out without the
addition of RT enzyme (-RT control; Figure 1, lanes 3 and
4), indicating no detectable contamination with genomic
DNA. A band representing the UCP1 product (489 kb) can
be seen in Figure 1, lane 6. The identity of this band as the
expected UCP1 product was confirmed by sequencing. A
second spurious band is also seen in lane 6 at 381 bp. This
product was also sequenced and BLAST searches [34] indi-
cated 98% homology to a region of the SAR1 gene on
10q22.1. There is only 13% homology between this prod-
uct and the UCP1 product, however there is an 8-base
region in the UCP1 forward primer and a 6-base sequence
in the UCP1 reverse primer that are identical to regions in
the SAR1 gene. These sequences immediately flank the
SAR1-like sequence obtained and may have served as an
anchor to allow amplification. We never detected UCP1
expression in the absence of the SAR1 band. As expected,
a 495 kb band derived from UCP2 is present in Figure 1,
lane 7 and its origin was also confirmed by sequencing.
Expression of UCP1 was also detected at low levels in the
murine beta cell line MIN-6 (Figure 2, lane 2), but was
absent in the murine glucagon-secreting cell line αTC1.6
(Figure 2, lane 6).
Immunohistochemistry of pancreatic sections
Results of the IHC experiments are shown in Figure 3.
UCP1 protein was detected in pancreatic tissue sections
from Macaca fascicularis (monkey), human, and mouse,
and co-localized with insulin in the islet cells of all three
species. As anticipated from its known mitochondrial
localization, UCP1 protein was only observed in the
cytosol.
UCP1 is expressed in human total pancreatic RNA: cDNAs  prepared in the absence or presence of reverse transcriptase  (RT) from total human pancreas RNA, were used for PCR  with the indicated primers Figure 1
UCP1 is expressed in human total pancreatic RNA: cDNAs 
prepared in the absence or presence of reverse transcriptase 
(RT) from total human pancreas RNA, were used for PCR 
with the indicated primers. The lane containing 1 Kb Plus 
DNA Ladder (M), and positions of UCP1 (489 bp) and UCP2 
products (495 bp) in the lanes corresponding to RT+ cDNA 
are indicated.
M                UCP1 UCP2           UCP1 UCP2
RT –– –– +       +
UCP1/UCP2
M                UCP1 UCP2           UCP1 UCP2
RT –– –– +       +
UCP1/UCP2
Table 3: Significant association results between UCP1 and UCP2 SNPs and traits in populations from the IRAS Family Study
Trait Population Gene SNP Allele 1/
Allele 2
Mean ± SE 1/1 
(n)
Mean ± SE 1/2 
(n)
Mean ± SE 2/2 
(n)
P-value 
(General)
P-value 
(Dom)
P-Value 
(Add)
P-value 
(Rec)
AIRg
a Los Angeles UCP1 A3826G A/G 669.4 ± 86.3 (42) 954.2 ± 83.9 (93) 894.7 ± 65.1 (98) 0.017 0.006 0.366 0.786
AIRg
a San Luis 
Valley
UCP1 A3826G A/G 718.4 ± 110.5 (74) 867.3 ± 81.9 (117) 855.9 ± 80.2 (23) 0.161 0.054 0.093 0.366
BMIb San Antonio UCP2 A55V C/T 29.2 ± 0.82 (115) 28.7 ± 0.54 (210) 30.3 ± 0.71 (116) 0.040 0.968 0.220 0.018
Waistb Los Angeles UCP2 A55V C/T 88.1 ± 0.60 (76) 87.1 ± 0.49 (139) 89.4 ± 0.67 (54) 0.045 0.440 0.510 0.065
WHRb Los Angeles UCP2 G-866A G/A 0.82 ± 0.005 (77) 0.81 ± 0.005 (130) 0.83 ± 0.007 (51) 0.016 0.237 0.863 0.037
HDLa San Antonio UCP1 A3826G A/G 40.2 ± 1.14 (164) 42.8 ± 1.10 (217) 44.9 ± 1.46 (66) 0.001 0.015 0.0004 0.006
Empirical P-values are shown. aAdjusted for age, sex and BMI; badjusted for age and sex. General: General model; Dom: Dominant model; Add: 
Additive model; Rec: Recessive model. Bold: P < 0.05.BMC Endocrine Disorders 2007, 7:1 http://www.biomedcentral.com/1472-6823/7/1
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Discussion
As anticipated, associations were detected between geno-
typed SNPs and metabolic traits, particularly with meas-
ures related to adiposity: UCP2  SNPs with waist
circumference, BMI and waist-to-hip ratio, although sig-
nificance levels for these associations were modest (Table
3). An association between UCP1 A-3826G and HDL-C
levels in SA families (P = 0.0004) was also detected. The
association between UCP1 A-3826G and AIRg in the AA
families from the IRAS Family Study was unexpected,
since UCP1 has not been reported to be expressed in the
pancreas.
In both the original IRAS cohort [35], and the IRAS Family
Study [32], AIRg was found to be higher in non-diabetic
African Americans than non-Hispanic whites or Hispan-
ics. Carrying either the UCP1 3826G allele or the rare 64T
allele increases AIRg (although the latter association was
not statistically significant). The higher frequency of
3826G in the African American families investigated
appears to at least partially explain the higher AIRg values.
We did not find significant association with AIRg using
haplotype analysis of the two UCP1 SNPs, and there is
insufficient power in the present study design to investi-
gate whether the presence of the two SNPs in trans show
an interaction. Interestingly, threonine is present at posi-
tion 64 in dog, mouse, rat, hamster, rabbit, Arabidopsis
and Solanum Ucp1, and also present in human UCP2 and
UCP3, although alanine is the more common amino acid
in UCP1 of humans. It is not known what effect substitut-
ing a hydrophilic amino acid (threonine) for a hydropho-
bic residue (alanine) at this position has on protein
function, especially in relation to insulin secretion.
While UCP2 is expressed in a variety of tissues [36], UCP1
expression was believed to be largely restricted to brown
adipose tissue (BAT) [36-38]. However, expression of ucp1
in mouse brain, skeletal muscle [39] and uterus [40], and
rat thymus [41] have been reported. The rapid insulin
response measured by AIRg is generally believed to be a
measure of beta cell function, and we therefore sought to
explain the biological impact of UCP1 on AIRg by investi-
gating the expression of this gene in the pancreas. Detec-
tion of UCP1 expression in human pancreas by RT-PCR is
a novel finding. We confirmed the presence of UCP1 in
human pancreas by IHC and found the UCP1 protein co-
localized with insulin in the islets. Further, RT-PCR of the
murine beta cell line MIN-6 demonstrated the presence of
UCP1 expression in beta cells, while UCP1 mRNA could
not be detected in the murine alpha cell derived line
αTC1.6.
UCP2 is known to be expressed in pancreatic islets, where
it is upregulated by glucolipotoxic conditions, and
increased UCP2 expression decreases glucose-stimulated
insulin secretion [42,43]. Even though UCP2 G866A has
been reported by others as influencing glucose-induced
insulin secretion [3-5], we did not see any association
between this SNP and AIRg. Over-expression studies of
ucp1 in INS-1 cells have shown that ucp1 upregulation
also suppresses insulin secretion [44], while studies of
adipose tissues indicated that the promoter -3826G allele
decreases  UCP1  expression [45]. Assuming the same
impact on expression is true in human beta cells, this
would be consistent with the increased first-phase insulin
response (or lack of suppression) seen individuals from
Los Angeles and San Luis Valley with one or two copies of
the UCP1 -3826G allele.
The polygenic regulation of AIRg, and implication from
expression studies that other sequence variants are likely
to influence UCP1 expression [45], may explain the more
modest effects (San Luis Valley) or lack of association
(San Antonio) seen between UCP1 A-3826G and AIRg in
the two Hispanic populations.
Associations between UCP2 SNPs and waist or WHR were
modest and have not been reported previously, although
UCP2 G-866A and A55V have been reported as associated
with BMI [46-48], and G-866A associated with obesity [8]
and adipose tissue levels [4]. The -866A allele is associated
with enhanced UCP2 mRNA expression in adipose tissue
[8], possibly via PAX6  transactivation [49]. However,
Ucp1 is expressed in an insulin producing cell line: cDNAs  prepared in the absence or presence of reverse transcriptase  (RT) from total RNA isolated from MIN-6 and αTC1.6 cells,  were used for PCR with the indicated primers Figure 2
Ucp1 is expressed in an insulin producing cell line: cDNAs 
prepared in the absence or presence of reverse transcriptase 
(RT) from total RNA isolated from MIN-6 and αTC1.6 cells, 
were used for PCR with the indicated primers. The lane con-
taining 100 bp marker (M), and positions of Ucp1 and Ucp2 
products are indicated. A band corresponding to Ucp1 (505 
bp) can be clearly seen in the lane corresponding to RT+ 
MIN-6 cDNA. Expression of Ucp2 (608 bp) can be seen in 
both insulin and glucagon producing cell lines.BMC Endocrine Disorders 2007, 7:1 http://www.biomedcentral.com/1472-6823/7/1
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commonly reported associations between obesity and the
UCP1 SNPs genotyped were not detected. The reported
association between UCP1 A-3826G and obesity in Span-
ish women [50] was not observed in Hispanic families,
possibly due to different environmental interactions. The
smallest P-value for this SNP with the 2 degree-of freedom
general test of association and measures of obesity was P
= 0.14 for BMI in San Luis Valley women.
Interestingly, the same UCP1 SNP associated with high
AIRg in AA, 3826G, was also significantly associated with
higher HDL-C levels in the Hispanic SA families, although
it should be noted that this SNP deviated from HW pro-
portions (P = 0.034) in the 73 founders in this popula-
tion. In a study of 312 Japanese women, there was a non-
significant trend for women carrying the 3826G allele to
have higher HDL levels than non-carriers, in both pre-
menopausal (P = 0.14) and postmenopausal (P = 0.29)
groups [51]. However a study of 118 obese Polish subjects
showed 3826G/G homozygotes (n = 17) had significantly
lower levels of HDL-C than AA homozygotes (n = 63) (P =
0.004) [52], opposite to the results observed in the SA
families of the IRAS Family Study.
Tests of association for additional traits (such as hyperten-
sion and coagulation factors) that were not part of our a
priori  hypotheses for either UCP1  or  UCP2  were con-
ducted during automated analytical procedures. After
UCP1 and insulin co-localize in mammalian islet cells Figure 3
UCP1 and insulin co-localize in mammalian islet cells. Pancreas sections from monkey (Macaca fascicularis), human, and mouse 
(indicated at left, together with magnification) were stained using immunohistochemistry with anti-UCP1 (left); anti-Insulin 
(middle); or double-stained with anti-UCP1 and anti-Insulin (right). Sections stained with anti-UCP1 were visualized with Vec-
tor Red, resulting in pink staining of the islet cells, seen in the left panel for each species. Gal-X visualization of anti-Insulin pro-
duced a light blue stain of islet cell cytoplasm, seen in the middle panel for each species. Co-localization (overlay) of both anti-
UCP1 (pink) and anti-Insulin (light blue) stains produced the purple staining of the islets seen in the third panel for each species. 
Examples of islet cells with cytoplasmic staining for the proteins of interest are indicated by the arrows.BMC Endocrine Disorders 2007, 7:1 http://www.biomedcentral.com/1472-6823/7/1
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Bonferroni correction for 5 SNPs × 21 traits × 4 models +
4 haplotypic analyses, none of the reported associations
would maintain significance. However, all tests can not be
considered entirely independent due to correlations
between SNPs and across phenotypes, so this approach
may be overly conservative. Additionally, we did not con-
sider the inheritance models unless the general test of
association was significant. While a trend between UCP1
3826G and higher HDL-C levels detected in the SA popu-
lation has been reported previously [51], clearly replica-
tion of the association between this SNP and AIRg in other
populations will be needed to confirm this finding.
Conclusion
We have confirmed the previously-reported association
between UCP1 A-3826G and HDL-C levels in a Hispanic
population from the IRAS Family Study. We also found a
novel association between UCP1 A-3826G and AIRg in an
African American population, and detected UCP1 expres-
sion in primate and mouse islet cells. These results suggest
that UCP1 may have a previously unsuspected role in first-
phase insulin release. Further studies of the influence of
variants of the UCP1 gene on AIRg in other populations,
and investigations of the interplay between UCP1 and
UCP2 on glucose-stimulated insulin secretion, are war-
ranted.
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